Skip to main content

Advertisement

SpringerLink
Log in

Can Oxytocin Enhance Social Affiliation in Schizophrenia?

  • Psychosis (A Ahmed, Section Editor)
  • Published:
Current Behavioral Neuroscience Reports Aims and scope Submit manuscript

Abstract

Schizophrenia is a chronic, persistent, and severe mental illness characterized by deficits in cognition in addition to the well-established positive and negative symptoms. Impairment in cognition has been a keen area of research that has received a lot of attention in the last two decades. Several cognitive domains, including social cognition, are impaired in schizophrenia. Social cognition in schizophrenia is a rapidly emerging and major focus of schizophrenia research since deficits in various domains of social cognition lead to poorer outcomes and functioning. Although antipsychotic medications are effective in treating the positive and to some extent negative symptoms of schizophrenia, no pharmacological agents currently exist that are approved for treatment of impairment in social cognition associated with schizophrenia. Several studies have shown that oxytocin, a neurohormone, improves social affiliations in schizophrenia. Meta-analyses of such studies have demonstrated beneficial effect of oxytocin in the treatment of social cognitive impairments in schizophrenia in addition to having some adjunctive value in treating positive and negative symptoms. The role of oxytocin as an adjunct in the treatment of schizophrenia is based on the premise that oxytocin may have some role in the pathophysiology of schizophrenia in conjunction with several neurotransmitters. This review focuses on bringing the reader up-to-date on the subject with the main focus being on the latest research findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. doi:10.1093/epirev/mxn001.

    Article  PubMed  Google Scholar 

  2. Pfueller U, Roesch-Ely D, Mundt C, Weisbrod M. Treatment of cognitive deficits in schizophrenia. Part 1: diagnostic and psychological training. Nervenarzt. 2010;81(5):556–63. doi:10.1007/s00115-009-2923-x.

    Article  CAS  PubMed  Google Scholar 

  3. Kirkpatrick B, Fenton WS, Carpenter Jr WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Young J, Geyer M. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol. 2015;29:178–96. This article reviews challenges in cross-species translational research in cognitive neurosciences and presents a behavioral framework in relation to schizophrenia.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–30.

    Article  CAS  PubMed  Google Scholar 

  6. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33:2061–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sarnyai Z, Kovács GL. Oxytocin in learning and addiction: from early discoveries to the present. Pharmacol Biochem Behav. 2014;119:3–9. doi:10.1016/j.pbb.2013.11.019.

    Article  CAS  PubMed  Google Scholar 

  8. MacDonald K, Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatrica. 2012;24:130–14. doi:10.1111/j.1601-5215.2011.00634.x.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. 2008;34:1211–20.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pinkham AE, Penn DL, Green MF, Buck B, Healey K, Harvey PD. The social cognition psychometric evaluation study: results of the expert survey and RAND panel. Schizophr Bull. 2013. doi:10.1093/schbul/sbt081.

    Google Scholar 

  11. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–51.

    Article  PubMed  Google Scholar 

  12. Penn D, Ritchie M, Francis J, Combs D, Martin J. Social perception in schizophrenia: the role of context. Psychiatry Res. 2002;109:149–59.

    Article  PubMed  Google Scholar 

  13. Green MF, Leitman DI. Social cognition in schizophrenia. Schizophr Bull. 2008;34:670–2.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Green MF, Bearden CE, Cannon TD, Fiske AP, Hellemann GS, Horan WP, et al. Social cognition in schizophrenia, part 1: performance across phase of illness. Schizophr Bull. 2012;38(4):854–64.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Sprong M, Schothorst P, Vos E, Hox J, van Engeland H. Theory of mind in schizophrenia: meta-analysis. Br J Psychiatry. 2007;191:5–13.

    Article  PubMed  Google Scholar 

  16. Mehta UM, Thirthalli J, Subbakrishna DK, Gangadhar BN, Eack SM, Keshavan MS. Social and neuro-cognition as distinct cognitive factors in schizophrenia: a systematic review. Schizophr Res. 2013;148(1–3):3–11. doi:10.1016/j.schres.2013.05.009.

    Article  PubMed  Google Scholar 

  17. Kucharska-Pietura K, David AS, Masiak M, Phillips ML. Perception of facial and vocal affect by people with schizophrenia in early and late stages of illness. Br J Psychiatry. 2005;187:523–8.

    Article  PubMed  Google Scholar 

  18. Bora E, Yucel M, Pantelis C. Theory of mind impairment in schizophrenia: meta-analysis. Schizophr Res. 2009;109(1–3):1–9. doi:10.1016/j.schres.2008.12.020.

    Article  PubMed  Google Scholar 

  19. Kaney S, Bentall RP. Persecutory delusions and attributional style. Br J Med Psychol. 1989;62:191–8.

    Article  PubMed  Google Scholar 

  20. Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35(3):573–88. doi:10.1016/j.neubiorev.2010.07.001.

    Article  PubMed  Google Scholar 

  21. Ventura J, Wood RC, Hellemann GS. Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis. Schizophr Bull. 2013;39:102–11. This article explores the nature and the relative strength of link between schizophrenia symptoms and neurocognition to social cognitive deficits.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Waldheter EJ, Jones NT, Johnson ER, Penn DL. Utility of social cognition and insight in the prediction of inpatient violence among individuals with a severe mental illness. J Nerv Ment Dis. 2005;193:609–18.

    Article  PubMed  Google Scholar 

  23. McNeil DE, Eisner JP, Binder RL. The relationship between aggressive attributional style and violence by psychiatric patients. J Consult Clin Psychol. 2003;71:399–403.

    Article  Google Scholar 

  24. Abu-Akel A, Abushua’leh K. ‘Theory of mind’ in violent and nonviolent patients with paranoid schizophrenia. Schizophr Res. 2004;69:45–53.

    Article  PubMed  Google Scholar 

  25. Antonius D, Kline B, Sinclair SJ, White-Ajmani M, Gianfagna S, Malaspina D, et al. Deficits in implicit facial recognition of fear in aggressive patients with schizophrenia. Schizophr Res. 2013;143:401–2.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ahmed AO, Hunter KM, Van Houten EG, Monroe JM, Bhat IA. Cognition and other targets for the treatment of aggression in people with schizophrenia. Ann Psychiatry Ment Health. 2014;2(1):1004.

    Google Scholar 

  27. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006;26:365–84. doi:10.1007/s10571-006-9062-8.

    Article  CAS  PubMed  Google Scholar 

  28. Foster DJ, Choi DL, Conn PJ, Rook JM. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183–91. doi:10.2147/NDT.S5510421.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Deidda G, Bozarth IF, Cancedda L. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci. 2014;8:119. doi:10.3389/fncel.2014.0011922.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Meneses A. Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative. Rev Neurosci. 2014;25:325–56. doi:10.1515/revneuro-2014-000123.

    CAS  PubMed  Google Scholar 

  31. Di Pilato P, Niso M, Adriani W, Romano E, Travaglini D, Berardi F, et al. Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview. Rev Neurosci. 2014;25:401–15. doi:10.1515/revneuro-2014-000924.

    Article  PubMed  Google Scholar 

  32. LaCrosse AL, Olive MF. Neuropeptide systems and schizophrenia. CNS Neurol Disord Drug Targets. 2013;12:619–32. doi:10.2174/1871527311312050010.

    Article  CAS  PubMed  Google Scholar 

  33. Souza RP, Ismail P, Meltzer HY, Kennedy JL. Variants in the oxytocin gene and risk for schizophrenia. Schizophr Res. 2010;121:279–80. doi:10.1016/j.schres.2010.04.01928.

    Article  PubMed  Google Scholar 

  34. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol. 2010;13:793–8. doi:10.1017/S1461145710000167.

    Article  CAS  PubMed  Google Scholar 

  35. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81:629–83.

    CAS  PubMed  Google Scholar 

  36. Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci. 2006;7(2):126–36.

    Article  CAS  PubMed  Google Scholar 

  37. Loup F, Tribollet E, Dubois-Dauphin M, Pizzolato G, Dreifuss JJ. Localization of oxytocin binding sites in the human brainstem and upper spinal cord: an autoradiographic study. Brain Res. 1989;500:223–30.

    Article  CAS  PubMed  Google Scholar 

  38. Boccia ML, Petrusz P, Suzuki K, Marson L, Pedersen CA. Immunohistochemical localization of oxytocin receptors in human brain. Neuroscience. 2013;253:155–64. doi:10.1016/j.neuroscience.2013.08.048.

    Article  CAS  PubMed  Google Scholar 

  39. Bartholomeusz CF, Ganella EP, Labuschagne I, Bousman C, Pantelis C. Effects of oxytocin and genetic variants on brain and behaviour: implications for treatment in schizophrenia. Schizophr Res. 2015;168(3):614–27. doi:10.1016/j.schres.2015.06.007.

    Article  PubMed  Google Scholar 

  40. Bethlehem RA, van Honk J, Auyeung B, Baron-Cohen S. Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinol. 2013;38:962.

    Article  CAS  Google Scholar 

  41. Wigton R, Radua J, Allen P, Averbeck B, Meyer-Lindenberg A, McGuire P, et al. Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. J Psychiatry Neurosci. 2015;40(1):E1–22.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr Bull. 2011;37(5):1077–87. doi:10.1093/schbul/sbq015.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Young KA, Liu Y, Gobrogge KL, Wang H, Wang Z. Oxytocin reverses amphetamine-induced deficits in social bonding: evidence for an interaction with nucleus accumbens dopamine. J Neurosci. 2014;34:8499–506.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Carter CG, Wilkinson GS. Intranasal oxytocin increases social grooming and food sharing in the common vampire bad Desmodus rotundus. Horm Behav. 2015;75:150–3.

    Article  CAS  PubMed  Google Scholar 

  45. Ramos L, Hicks C, Caminer A, Goodwin J, McGregor IS. Oxytocin and MDMA (‘Ecstasy’) enhance social reward in rats. Psychopharmacology. 2015;232:2631–41.

    Article  CAS  PubMed  Google Scholar 

  46. Calcagnoli F, Stubbendorff C, Meyer N, de Boer SF, Althaus M, Koolhaas JM. Oxytocin microinjected into the central amygdaloid nuclei exerts anti-aggressive effects in male rats. Neuropharmacology. 2015;90:74–81.

    Article  CAS  PubMed  Google Scholar 

  47. Mizuno A, Cherepanov SM, Kikuchi Y, Fakhrul A, Akther S, Deguchi K, et al. Lipo-oxytocin-1, a novel oxytocin analog conjugated with two palmitoyl groups, has long-lasting effects on anxiety-related behavior and social avoidance in CD157 knockout mice. Brain Sci. 2015;5:3–13.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Parr L. Intranasal oxytocin enhances socially-reinforced learning in rhesus monkeys. Front Behav Neuroscience. 2014; 8: Article 278.

  49. Romero T, Nagasawa M, Mogi K, Hasegawa T, Kikusui T. Oxytocin promotes social bonding in dogs. PNAS Proc Natl Acad Sci USA. 2014;111:9085–90.

    Article  CAS  Google Scholar 

  50. Mooney SJ, Douglas NR, Holmes MM. Peripheral administration of oxytocin increases social affiliation in the naked mole-rat (Heterocephalus glaber). Horm Behav. 2014;65:380–5.

    Article  CAS  PubMed  Google Scholar 

  51. Teng BL, Nonneman RJ, Agster KL, Kikolova VD, Davis TT, Riddick NV, et al. Prosocial effects of oxytocin in two mouse models of autism spectrum disorders. Neuropharmacology. 2013;72:187–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Huang H, Michetti C, Busnelli M, Manago F, Sannino S, Scheggia D, et al. Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmcology. 2014;39:1102–14.

    Article  CAS  Google Scholar 

  53. Mogi K, Oovama R, Nagasawa M, Kikusui T. Effects of neonatal oxytocin manipulation on development of social behaviors in mice. Physiol Behav. 2014;133:68–75.

    Article  CAS  PubMed  Google Scholar 

  54. Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH, Neumann ID. The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology. 2013;36:2159–68.

    Article  Google Scholar 

  55. Rault J-L, Carter SC, Garner JP, Marchant-Forde JN, Richert BT, Lay Jr DC. Repeated intranasal oxytocin administration in early life dysregulates the HPA axis and alters social behavior. Physiol Behav. 2013;112–113:40–8.

    Article  PubMed  Google Scholar 

  56. Gibson CM, Penn DL, Smedley KL, Leserman J, Elliott T, Pedersen CA. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr Res. 2014;156:261–5.

    Article  PubMed  Google Scholar 

  57. Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011;132:50–3.

    Article  PubMed  Google Scholar 

  58. Averbeck BB, Bobin T, Evans S, Shergill SS. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med. 2012;42:259–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Goldman MB, Gomes AM, Carter CS, Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology. 2011;216:101–10.

    Article  CAS  PubMed  Google Scholar 

  60. Fischer-Shofty M, Brune M, Ebert A, Shefet D, Levkovitz Y, Shamay-Tsoory SG. Improving social perception in schizophrenia: the role of oxytocin. Schizophr Res. 2013;147:257–362. An excellent study examining multiple forms of social perception, including perception of kinship and intimate relationships.

    Google Scholar 

  61. Davis MC, Lee J, Horan WP, Clarke AD, McGee MR, Green MF, et al. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res. 2013;147:393–7. A study that differentiated higher-level social cognition and lower-level social cognition. The study found that participants administered oxytocin demonstrated improvements in higher-level but not lower-level social cognition.

    Article  PubMed  Google Scholar 

  62. Woolley JD, Chuang B, Lam O, Lai W, O’Donovan A, Rankin KP, et al. Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology. 2014;47:116–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, et al. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr Bull. 2015;41:483–93.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Shin NY, Park HY, Jung WH, Park JW, Yun JY, Jang JH, et al. Effects of oxytocin on neural response to facial expressions in patients with schizophrenia. Neuropsychopharmacol. 2015;40:1919–27.

    Article  CAS  Google Scholar 

  65. Horta de Macedo LR LR, Zuardi AW, Machado-de-Sousa JP, Chagas MH, Hallack JE. Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task. Psych Res. 2014;20:125–8.

    Article  Google Scholar 

  66. Dagani J, Sisti D, Abelli M, Di Paolo L, Pini S, Raimondi S, et al. Do we need oxytocin to treat schizophrenia? A randomized clinical trial. Schizophr Res. 2016.

  67. Bukovskaya O, Shmukler A. Oxytocin and social cognitions in schizophrenia: a systematic review. Psychiatr. Q. 2015; No pagination specified.

  68. Rich ME, Caldwell HK. A role for oxytocin in the etiology and treatment of schizophrenia. Front Endocrinol. 2015;6:90.

    Article  Google Scholar 

  69. Guastella AJ, Ward PB, Hickie IB, Shahrestani S, Hodge MAR, Scott EM, et al. A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia. Schizophr Res. 2015;168:628–33. This study replicated the results derived from the study by Davis et al., demonstrating that participants administered oxytocin exhibited improvements in higher-level social cognition but did not improve significantly on lower-level social cognition.

    Article  PubMed  Google Scholar 

  70. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010;68:678–80.

    Article  CAS  PubMed  Google Scholar 

  71. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berlin). 2004;174:45–53.

    Article  CAS  Google Scholar 

  72. Ahmed AO, Bhat IA. Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets. CNS Drugs. 2014;28(4):301–18.

    Article  CAS  PubMed  Google Scholar 

  73. Talpos J, Steckler T. Touching on translation. Cell Tissue Res. 2013;354:297–308.

    Article  PubMed  Google Scholar 

  74. Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013;39:417–35.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Lee HJ, Macbeth AH, Pagani JH, Young WS. Oxytocin: the great facilitator of life. Prog Neurobiol. 2009;88(2):127–51. doi:10.1016/j.pneurobio.2009.04.001.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Goldman M, Marlow-O’Connor M, Torres I, Carter CS. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res. 2008;98(1–3):247–55.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Feifel D. Is oxytocin a promising treatment for schizophrenia? Expert Rev Neurother. 2011;11(2):157–9. doi:10.1586/ern.10.199.

    Article  CAS  PubMed  Google Scholar 

  78. Frost K, Keller W, Buchanan R, Gold J, Koenig J, Ossenfort K, et al. Plasma oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. Arch Clin Neuropsychol. 2014;29(6):577–8.

    Article  Google Scholar 

  79. Cochran DM, Fallon D, Hill M, Frazier JA. The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings. Harv Rev Psychiatry. 2013;21(5):219–47. doi:10.1097/HRP.0b013e3182a75b7d.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res. 2010;124(1–3):13–21. doi:10.1016/j.schres.2010.09.014.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Uvnas-Moberg KU, Alster P, Svensson TH. Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology (Berlin). 1992;109(4):473–6. doi:10.1007/BF02247726.

    Article  CAS  Google Scholar 

  82. Kaneda Y, Jayathilak K, Meltzer H. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry Res. 2010;178:57–62. doi:10.1016/j.psychres.2009.04.001.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Health Behavior, Medical College of Georgia at Augusta University, Augusta, GA, USA

    Ishrat Bhat & Anjum Ara

  2. Westchester Division-Weill Cornell Department of Psychiatry, New York Presbyterian Hospital, New York, NY, USA

    Alex S. Buckner

Authors
  1. Ishrat Bhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex S. Buckner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anjum Ara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ishrat Bhat.

Ethics declarations

Conflict of Interest

Dr. Ishrat Bhat, Mr. Alex S. Buckner, and Dr. Anjum Ara declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Psychosis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhat, I., Buckner, A.S. & Ara, A. Can Oxytocin Enhance Social Affiliation in Schizophrenia?. Curr Behav Neurosci Rep 3, 131–143 (2016). https://doi.org/10.1007/s40473-016-0080-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40473-016-0080-7

Keywords

Search

Navigation